MicroRNAs as Prognostic Biomarkers and Therapeutic Targets in Chondrosarcoma
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25063176 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Palina Skipar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Cancer Research Institute in Warsaw, 02-781 Warsaw, Poland. Hauptthemen laut MEDLINE: MicroRNAs, Chondrosarcoma, Bone Neoplasms, Neoplasms, Second Primary. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education.
Abstract (Originalsprache)
Chondrosarcoma, the second most common primary malignant bone tumor, originates from cartilaginous tissue and accounts for almost 20% of all primary bone tumors. The management of chondrosarcoma remains challenging due to its diverse clinical course and prognosis, which can range from benign to highly aggressive with a huge risk of metastasis. Emerging research has demonstrated the importance of microRNA (miRNA) dysregulation in the pathogenesis of chondrosarcoma. MiRNAs are small, noncoding RNA molecules that play an essential role in gene expression regulation by targeting specific messenger RNAs (mRNAs) for degradation or translational repression. This article provides an extensive review of current miRNA research in chondrosarcoma, focusing on diagnostic strategies, cell cycle regulation, drug resistance, biomarkers of progression, and stem cell phenotype. We will examine recent studies identifying differentially expressed miRNAs in chondrosarcoma compared to normal cartilage tissue, exploring their potential as diagnostic and prognostic biomarkers. Furthermore, we will discuss the role of miRNAs in regulating cell cycle progression and their potential as therapeutic targets to overcome drug resistance. We will also investigate the prospective utility of miRNAs as biomarkers of progression and their role in modulating the stem cell phenotype of chondrosarcoma cells. This article offers a comprehensive analysis of current miRNA research in chondrosarcoma, focusing on its potential as diagnostic and prognostic biomarkers, therapeutic targets, and regulators of disease progression. By integrating the latest discoveries in this field, we aim to contribute to the development of novel approaches to the prevention, diagnosis, and treatment of chondrosarcoma, ultimately enhancing patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Cancer Research Institute in Warsaw, 02-781 Warsaw, Poland.
- Faculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland.
- Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, 02-106 Warsaw, Poland.
- Department of Experimental Pharmacology, Mossakowski Medical Research Centre Polish Academy of Sciences, 02-106 Warsaw, Poland.
ORCID-Profile: Palina Skipar, Mritunjoy Dey, Jakub Piątkowski, Dorota Sulejczak, Piotr Rutkowski, Anna M Czarnecka
Förderung
- Ministry of Science and Higher Education
Zitieren
APA
Skipar, P., Dey, M., Piątkowski, J., Sulejczak, D., Rutkowski, P., & Czarnecka, A. M. (2024). MicroRNAs as Prognostic Biomarkers and Therapeutic Targets in Chondrosarcoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25063176
Vancouver
Skipar P, Dey M, Piątkowski J, Sulejczak D, Rutkowski P, Czarnecka AM. MicroRNAs as Prognostic Biomarkers and Therapeutic Targets in Chondrosarcoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25063176
BibTeX
@article{Skipar2024,
author = {Skipar, Palina and Dey, Mritunjoy and Piątkowski, Jakub and Sulejczak, Dorota and Rutkowski, Piotr and Czarnecka, Anna M},
title = {MicroRNAs as Prognostic Biomarkers and Therapeutic Targets in Chondrosarcoma},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25063176}
}
EUVIMED